Physician profile
David Tavdy
NPI 1710936232
$11,566.71
in general payments reported to CMS, 2019-2025
52 companies · $978 in 2025
The $978 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,380 · 2020: $1,209 · 2021: $1,363 · 2022: $1,845 · 2023: $1,874 · 2024: $1,917 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,769.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,974.30 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $1,351.30 | 2019-2024 | Lokelma, Farxiga, Airsupra |
| Novo Nordisk INC | $1,012.62 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $722.29 | 2019-2025 | |
| Lilly USA, LLC | $716.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $673.14 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $483.01 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $400.79 | 2021-2025 | |
| Cequr Corporation | $315.65 | 2022-2024 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.18 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Acadia Pharmaceuticals INC | $240.72 | 2022-2024 | Nuplazid |
| Janssen Pharmaceuticals, INC | $211.64 | 2019 | |
| Abbott Laboratories | $197.59 | 2024-2025 | Gallant, Freestyle Libre 3, Aveir |
| Mannkind Corporation | $179.13 | 2019-2023 | V-Go |
| Philips North America LLC | $154.44 | 2019-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tavdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.